Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An overview is given of serum and urine prostate cancer markers that are currently under investigation and subsequently the P-Mark project is introduced. There are many markers showing promise to overcome the limitations of prostate specific antigen (PSA). Eventually, these markers should be able to increase the specificity in diagnosis, differentiate between harmless and aggressive disease and identify progression towards androgen independence at an early stage. In the P-Mark project, several recently developed, promising markers will be evaluated using clinically well-defined biorepositories. Following successful evaluation, these markers will be validated on a sample set derived from two large, European, prostate cancer studies and used for the identification of special risk groups in the general population. In addition, novel markers will be identified in the same biorepositories by different mass spectrometry techniques.

Original publication

DOI

10.1016/j.eururo.2005.06.009

Type

Journal article

Journal

Eur Urol

Publication Date

12/2005

Volume

48

Pages

1031 - 1041

Keywords

Biomarkers, Tumor, Bone Morphogenetic Protein 6, Bone Morphogenetic Proteins, Humans, Male, Mass Spectrometry, Neoplasm Staging, Prognosis, Prostate-Specific Antigen, Prostatic Neoplasms, Risk Assessment, Sensitivity and Specificity, Survival Analysis, Tissue Kallikreins